A New Promising Pathway in Aggressive Prostate Cancer: Treg/mir-let8c/lin28b

Akalın, İbrahim; Erol, Bülent; Aslan, Ezgi; Ozkanli, S.; Efiloğlu, Özgür; Yıldırım, Şule; Çaşkurlu, Turhan; Yıldırım, Asıf; Karaman, M.

doi:10.37554/en-20210424-3467-19

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Derived from MDA PC 2b cells, exosomal miR-141-3p was identified as a key promoter of osteoblast activity and as a regulator of the bone metastatic microenvironment [ 89 ]. Akalin et al’s (2022) study suggests a potential diagnostic value for miR-141-3p in identifying aggressive PC [ 90 ]. Our findings reported no significant alteration in serum exosomal miR-141-3p expression in mCRPC patients.…”

Section: Discussionmentioning

confidence: 99%

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Evin,

Evinová,

Baranovičová

et al. 2024

IJMS

View full text Add to dashboard Cite

Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease due to the absence of effective therapies. A more comprehensive understanding of molecular events, encompassing the dysregulation of microRNAs (miRs) and metabolic reprogramming, holds the potential to unveil precise mechanisms underlying mCRPC. This study aims to assess the expression of selected serum exosomal miRs (miR-15a, miR-16, miR-19a-3p, miR-21, and miR-141a-3p) alongside serum metabolomic profiling and their correlation in patients with mCRPC and benign prostate hyperplasia (BPH). Blood serum samples from mCRPC patients (n = 51) and BPH patients (n = 48) underwent metabolome analysis through 1H-NMR spectroscopy. The expression levels of serum exosomal miRs in mCRPC and BPH patients were evaluated using a quantitative real-time polymerase chain reaction (qRT-PCR). The 1H-NMR metabolomics analysis revealed significant alterations in lactate, acetate, citrate, 3-hydroxybutyrate, and branched-chain amino acids (BCAAs, including valine, leucine, and isoleucine) in mCRPC patients compared to BPH patients. MiR-15a, miR-16, miR-19a-3p, and miR-21 exhibited a downregulation of more than twofold in the mCRPC group. Significant correlations were predominantly observed between lactate, citrate, acetate, and miR-15a, miR-16, miR-19a-3p, and miR-21. The importance of integrating metabolome analysis of serum with selected serum exosomal miRs in mCRPC patients has been confirmed, suggesting their potential utility for distinguishing of mCRPC from BPH.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Evin,

Evinová,

Baranovičová

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…miRNAs are small non-coding RNAs and are part of the epigenetic machinery that can regulate the expression of genes; therefore, increasingly altered mechanisms are identified due to the malfunction of these miRNAs, for example, it has been observed that several miRNAs dysregulated in PCa, are related to the regulatory T cell marker FOXP3, suggesting a relationship between immune cells, miRNAs and PCa ( 16 ). Therefore, the identification of dysregulated miRNAs could have implications both in understanding the pathology and in identifying possible targets for the detection, prognosis and treatment of various cancers ( 17 , 18 ).…”

Section: Discussionmentioning

confidence: 99%

Deletion in a regulatory region is associated with underexpression of miR-148b‑3p in patients with prostate cancer

Bergez‑Hernández,

Luque‑Ortega,

García‑Magallanes

et al. 2024

Biomed Rep

View full text Add to dashboard Cite

Prostate cancer (PCa) is the leading cause of cancer-related death in men. This pathology is complex and heterogeneous; therefore, elucidating the molecular mechanisms that lead to its origin and progression is imperative. MicroRNAs (miRNAs or miRs) are part of the epigenetic machinery that regulates the expression of human genes, therefore, mutations in the genes that encode them can lead to a dysregulation in their expression, which directly impacts their target genes, which could be oncogenes or tumor suppressor genes. In PCa several dysregulated expression levels of miRNAs are associated with perturbed cellular processes. A differential expression of miRNAs such as miR-145-5p and miR-148-3p has been observed in PCa, possibly due to mutations in regions near the miRNAs. However, the molecular mechanisms that lead to the dysregulation of these miRNAs still need to be clarified. Therefore, the present study aimed to analyze the expression of miRNAs and their relationship with mutations in patients with and without PCa. In total, 71 patients were analyzed: 41 of whom had PCa (CAP group) and 30 with benign pathology (BPD group). Underexpression was observed in miR-145-5p and miR-148b-3p in PCa patients (P=0.03 and P=0.001, respectively). In miR-145-5p, no mutations related to its expression were identified. For miR-148b-3p, a set of mutations were identified in the chr12:54337042/54337043 region, which were grouped into the mutation named DelsAAG. Although this mutation's abnormal allele is related to PCa (P=0.017), a statistically significant difference was observed in the expression of miR-148b-3p between carriers and non-carriers of the mutated allele, identifying a mechanism likely to be involved in the miR-148b-3p dysregulation.

show abstract

“…Sharma and Baruch (2019) identified miR-141 as a promising marker for metastatic prostate cancer [82]. Akalin et al's (2022) study suggests potential diagnostic value for miR-141-3p in identifying aggressive prostate cancer [83]. In a meta-analysis by Ye et al (2020), encompassing seven studies and 414 prostate cancer patients, miR-141 demonstrated diagnostic sensitivity and specificity of 0.70 (95% CI 0.64-0.75) and 0.73 (95% CI 0.64-0.80), respectively [28].…”

Section: Discussionmentioning

confidence: 99%

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Evin,

Evinová,

Baranovičová

et al. 2024

Preprint

View full text Add to dashboard Cite

Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease due to the absence of effective therapies. A more comprehensive understanding of molecular events, encompassing the dysregulation of microRNAs (miRs) and metabolic reprogramming, holds the potential to unveil precise mechanisms underlying mCRPC. This study aims to assess the expression of selected serum exosomal miRs (miR-15a, miR-16, miR-19a-3p, miR-21, and miR-141a-3p) alongside serum metabolomic profiling and their correlation in patients with mCRPC and benign prostate hyperplasia (BPH). Blood serum samples from mCRPC patients (n=51) and BPH patients (n=48) underwent metabolome analysis through 1H-NMR spectroscopy. The expression levels of serum exosomal miRs in mCRPC and BPH patients were evaluated using quantitative real-time polymerase chain reaction (qRT‒PCR). The 1H-NMR metabolomics analysis revealed significant alterations in lactate, acetate, citrate, 3-hydroxybutyrate, and branched-chain amino acids (BCAAs, including valine, leucine, and isoleucine) in mCRPC patients compared to BPH patients. MiR-15a, miR-16, miR-19a-3p, and miR-21 exhibited a down-regulation of more than twofold in the mCRPC group. Significant correlations were predominantly observed between lactate, citrate, acetate, and miR-15a, miR-16, miR-19a-3p, and miR-21. The importance of integrating metabolome analysis of serum with selected serum exosomal miRs in mCRPC patients has been confirmed, suggesting their potential utility as clinical diagnostic markers.

show abstract

A New Promising Pathway in Aggressive Prostate Cancer: Treg/mir-let8c/lin28b

Cited by 5 publications

References 0 publications

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Deletion in a regulatory region is associated with underexpression of miR-148b‑3p in patients with prostate cancer

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About